If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
107.00    2.50 (2.42%)
Bid:
104.00
Ask:
108.00
Spread: 4.00 (3.846%)
Market Cap: £63.77m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Acquisition of Authlogics Ltd

10 Oct 2022 07:01

RNS Number : 2583C
Intercede Group PLC
10 October 2022
 

 Intercede Group PLC

("Intercede," "the Company" or the "Group'') 

Acquisition of Authlogics Ltd

Gives Intercede capability to address the whole authentication pyramid and increases addressable market by 10x

Intercede Group PLC (AIM: IGP), a leading supplier of Public Key Infrastructure Credential Management Software, is pleased to announce the acquisition of Authlogics Ltd ("Authlogics", the Acquisition"), a Multi Factor Authentication ('MFA') and Password Security Management ('PSM') software vendor, for initial consideration of £2.5 million (adjusted to approximately £2.0 million after net debt and working capital adjustments) plus a further deferred conditional and staged earnout payment of up to £3 million.

Acquisition highlights

· Strong strategic rationale: acquiring IP that will significantly expand Intercede's addressable market

· Accelerates Intercede's ability to meet the requirements of new regulatory standards

· Authlogics run rate recurring annual revenue of £0.5m further enhances Intercede's ARR

· Initial consideration will be satisfied using Intercede's existing cash resources

· Acquisition expected to be earnings enhancing in the financial year commencing 1 April 2023

· As also announced today, Intercede is trading in line with management expectations

Klaas van der Leest, CEO of Intercede Group, commented:

"The acquisition of Authlogics enables us to deliver on the strategic vision that we have shared with investors of addressing the entire authentication pyramid. We believe that the addition of the Authlogics products will allow us to support our customers and prospects wherever they are in their authentication journey, and to embrace a wider set of use cases. The deal also increases our recurring revenue base.

We are delighted to welcome the Authlogics team to the Group, along with their customers, partners and distributors."

FURTHER INFORMATION ON THE ACQUISITION 

Background To Authlogics

Authlogics is a UK headquartered business based in Bracknell and was founded in June 2015. A Multi Factor Authentication ('MFA') and Password Security Management ('PSM') software vendor, Authlogics is the only business to cover all three key authentication segments (password security management, password breach database and multi factor authentication) with a seamless integrated solution. The Company's award-winning products service over 50 customers with 44 annual recurring software contracts across the Finance, Government, Defence and Healthcare sectors.

Authlogics primarily sells into the Middle East through a blue-chip global partner network. Authlogics has a high degree of recurring revenue (more than 95%) and is expected to grow strongly over the next three years.

Authlogics revenue grew at a 61% compound rate between the financial years ending 30 June 2018 and the 30 June 2021. In the year ended 30 June 2021, Authlogics made a small profit after tax of £8,000.

Whilst the Acquisition is primarily an IP deal, Authlogics had £0.5m of annual recurring revenue ("ARR") as at 30 June 2022.

Strategic Rationale

Passwords remain pervasive throughout the cybersecurity market, despite the majority of data breaches arising due to compromised password credentials. Intercede has set out its strategic objective of supporting customers wherever they are on their passwordless journey by broadening the footprint across the authentication pyramid beyond our current position in the Public Key Infrastructure Credential Management System ('PKI CMS') segment.

During this calendar year, the strategic rationale has sharpened following the introduction of new regulatory standards (e.g. FIPS 201-3) in our core US federal and defence markets. These new regulations allow customers and prospects in these markets to begin to adopt technologies beyond PKI. The addition of the Authlogics products will, in a single step, allow us to address the entire authentication pyramid. This enlarges our addressable market more than 10-fold, and these markets are predicated to grow significantly over the next three years. We believe this enhanced combination ranging from Passwords to PKI will give Intercede a significant competitive advantage.

Furthermore, the PKI segment is complex and involves long sales and integration cycles. The MFA and PSM markets are characterised by simpler sales and integration cycles which should help with the Group's revenue visibility going forward. Authlogics provides exposure to markets outside of Europe which are less penetrated and provide Intercede with the opportunity to grow its international footprint and deliver increased revenue growth over time.

The Acquisition creates a broader product portfolio for Intercede. This portfolio is expected to grow to cover Single Sign On (SSO) and Ongoing Authorisation products which will further enhance Intercedes' client offering.

Acquisition terms

Four of the current Authlogics staff will become Intercede employees, including the two Authlogics founders.

Under the terms of the Acquisition, Intercede will pay:

· Initial consideration of £2.5 million on a debt free/cash free basis; plus

· further deferred conditional and staged earnout payment of up to £3 million.

The deferred consideration is subject to achievement of significant revenue growth targets on sales of Authlogics products by the enlarged Group in the three years to 30 June 2025. The initial consideration of £2.5 million before adjustments for net debt and working capital movement, will be satisfied using the Group's existing cash resources. The non-contingent multiple on the initial consideration is 5x ARR as at 30 June 2022.

The Intercede Board believe that the acquisition will be earnings accretive in the financial year commencing 1 April 2023.

 

 

 

 

ENQUIRIES

Intercede Group plc

Tel. + 44 (0)1455 558111

Klaas van der Leest

CEO

Nitil Patel

CFO

 

 

finnCap Ltd

Tel. + 44 (0)20 7220 0500

Simon Hicks/Fergus Sullivan

Corporate Finance

Tim Redfern/Charlotte Sutcliffe

ECM

 

For more information visit: www.intercede.com

About Intercede

Intercede is a cybersecurity company specialising in digital identities, derived credentials and access control, enabling digital trust in a mobile world.

Headquartered in the UK, with offices in the US, we believe in a connected world in which people and technology are free to exchange information securely, and complex insecure passwords become a thing of the past.

Our vision is to make the highest levels of cybersecurity available to organisations and consumers alike, solving complexity and scalability issues by managing high volumes of digital credentials.

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQUPGPWUUPPGBB
Date   Source Headline
23rd Jun 20267:00 amRNSFinal Results
15th Jun 20267:00 amRNS-RExtension of Partnership with Swissbit
20th May 20267:00 amRNS-RPartnership with OneSpan
19th May 20267:00 amRNSNotice of Results and Investor Presentation
11th May 20262:50 pmRNSShare Incentive Scheme
21st Apr 20267:00 amRNSNew Contract Upsell Orders and Renewal
9th Apr 20267:00 amRNSTrading Update, Renewals and New Contract Orders
17th Mar 20267:00 amRNSYear End Trading Update
17th Mar 20267:00 amRNSYear End Trading Update
9th Feb 202612:55 pmRNSHolding(s) in Company
15th Jan 202610:44 amRNSExercise of Options & Total Voting Rights
24th Dec 20257:00 amRNSExercise of Options & Total Voting Rights
2nd Dec 20251:05 pmRNSHolding(s) in Company
25th Nov 20257:01 amRNSNew Contract Awards and Renewals
25th Nov 20257:00 amRNSHalf-year Report
22nd Oct 20252:15 pmRNSNotice of Interim Results & Investor Presentation
13th Oct 20257:00 amRNSExercise of Options, PDMR Shareholding & TVR
10th Oct 202510:25 amRNSDirector/PDMR Shareholding
9th Oct 20251:02 pmRNSDirector/PDMR Shareholding
9th Oct 20257:00 amRNSTrading Update, New Contract awards and Renewals
25th Sep 20251:03 pmRNSResult of AGM
22nd Sep 20257:00 amRNSNon-Executive Director Change
22nd Aug 20257:00 amRNSIssue of Equity & Total Voting Rights
12th Aug 20257:00 amRNSNotice of AGM and release of Annual Report 2025
24th Jul 20257:00 amRNS-RFirst CMS to support FIDO enterprise attestation
22nd Jul 20257:00 amRNSGrowth Share Scheme Vesting and Award Allocation
3rd Jul 20257:00 amRNSNew Contract Orders and Renewals
25th Jun 20256:01 pmRNSDirector/PDMR Shareholding
25th Jun 20257:00 amRNSDirector/PDMR Shareholding
24th Jun 20257:00 amRNSFinal Results
22nd May 20253:14 pmRNSNotice of Results & Investor Presentation
7th May 20257:00 amRNSShare Incentive Scheme
1st May 20257:00 amRNS-RIntercede Collaborates with Microsoft and Yubico
8th Apr 20257:00 amRNSTrading Update
2nd Apr 20257:00 amRNSMomentum maintained with New Contract Orders
31st Mar 202511:48 amRNSHolding(s) in Company
12th Mar 20251:54 pmRNSDirector/PDMR Shareholding
12th Mar 20257:00 amRNSContinued Momentum with New Contract Orders
8th Jan 20257:00 amRNSContract Orders and Renewals
24th Dec 20247:00 amRNSTransaction in Own Shares
23rd Dec 20247:00 amRNSTransaction in Own Shares
19th Dec 20247:00 amRNSTransaction in Own Shares
13th Dec 20247:00 amRNSTransaction in Own Shares
11th Dec 20247:00 amRNSTransaction in Own Shares
10th Dec 20247:00 amRNSTransaction in Own Shares
5th Dec 20247:00 amRNSTransaction in Own Shares
2nd Dec 20247:00 amRNSTransaction in Own Shares
29th Nov 20247:00 amRNSTransaction in Own Shares
28th Nov 20247:00 amRNSTransaction in Own Shares
27th Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.